MDM4 is an essential disease driver targeted by 1q gain in Burkitt lymphoma
Jennifer Hüllein, Mikołaj Słabicki, Maciej Rosolowski, Alexander Jethwa, Stefan Habringer, Katarzyna Tomska, Roma Kurilov, Junyan Lu, Sebastian Scheinost, Rabea Wagener, Zhiqin Huang, Marina Lukas, Olena Yavorska, Hanne Helferich, René Scholtysik, , Thorsten Zenz
This study identifies MDM4 as a critical target of 1q gain in TP53wt Burkitt lymphoma, showing its role in evading cell cycle arrest and highlighting its therapeutic potential.
bioRxiv · Apr 9, 2018 · PreprintCancer Biology